Replies to post #183127 on Biotech Values

[DewDiligence]

The PBAC argued the [Sovaldi] costs were too high to treat Australia's 250,000 Hepatitis C sufferers and promised to review the decision in a year, when drug companies came back with a better price.

Australia is a sizable HCV market, but my ENTA valuation model ascribes no value to sales there—another way in which the model is conservative.